---
(S)-ketamine for Mild and Moderate AUD

(S)-ketamine in combination with psycho-social support to treat Mild and Moderate AUD

Goal:
Re-purpose and develop (S)-ketamine, in a proprietary formulation, as a marketed combined therapeutic to treat Mild and Moderate AUD.

Status:
Awakn has signed 18-month exclusive agreement with a European pharmaceutical company to test the suitability of a proprietary formulation of (S)-ketamine with Phase I completed.

Near-term Catalysts:

• Complete and announce results of investigative study into dissociative effects of proprietary formulation of (S)-ketamine
• Execute global licensing agreement for Phase I data of patent pending proprietary formulation of (S)-ketamine
• Submit IND application to FDA

(S)-KETAMINE TO TREAT MILD and MODERATE AUD – Timeline

Sign Up for Newsletter

MAIN OFFICE
Awakn Life Sciences Corp.
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada

© 2023 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy